Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer

BJU International

Volumn 107, Issue 12, 2011, Pages 1923-1929

  Wadhwa, Vivek K ^a   Weston, Robin ^a   Parr, Nigel J ^a  

^a WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

Author keywords

androgen deprivation therapy; bicalutamide; bone density; health related quality of life; osteoporosis; prostate cancer

Indexed keywords

BICALUTAMIDE; ESTRADIOL; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ABDOMINAL PAIN; ADULT; AGED; ANTHROPOMETRY; ANTIGEN DETECTION; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYNAMOMETRY; GYNECOMASTIA; HOT FLUSH; HUMAN; LIVER FUNCTION TEST; MALE; MASTALGIA; MUSCLE STRENGTH; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUADRICEPS FEMORIS MUSCLE; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL FUNCTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; BONE DENSITY; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MUSCLE STRENGTH; NITRILES; OSTEOPOROSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 79957865124     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09726.x     Document Type: Article

References (22)

1. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR,. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95: 981-9 (Pubitemid 36896715)
2. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R,. Sex or survival: tradeoffs between quality and quantity of life. J Clin Oncol 1991; 9: 328-34
3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64 (Pubitemid 40096612)
4. Smith MR, Goode M, Zietman L, McGovern FJ, Lee H, Finkelstein JS,. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546-53 (Pubitemid 41103742)
5. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S,. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localised or locally advanced prostate cancer. J Urol 2004; 171: 2272-6 (Pubitemid 38625450)
6. Smith MR, Finkelstein JS, McGovern FJ, et al,. Changes in body composition during androgen deprivation for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603 (Pubitemid 34158224)
7. Iversen P, Tyrrell CJ, Kaisary AV, et al,. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82
8. Tyrrell CJ, Kaisary AV, Iversen P, et al,. A randomised comparison of 'Casodex' 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56 (Pubitemid 28251992)
9. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ,. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003; 92: 690-4 (Pubitemid 37475806)
10. Planas J, Morote J, Orsola A, et al,. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 2007; 99: 812-5 (Pubitemid 46439570)
11. Wadhwa VK, Weston R, Mistry R, Parr NJ,. Long term changes in bone mineral density and predicted fracture risk in patients receiving androgen deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009; 104: 800-5
12. Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T,. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer and Prostate Disease. 2001; 4: 196-203 (Pubitemid 34048480)
13. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP,; Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-54
14. Heidenrich A, Aus G, Abbou CC, et al,. European Association of Urology Guidelines on Prostate. Cancer 2009; 3: 80-1
15. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M,. Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 2004; 328: 382
16. Hertel KL, Trahotis MG,. Exercise in the prevention and treatment of osteoporosis: the role of physical therapy and nursing. Nurs Clin North Am 2001; 36: 441-53
17. Higano CS,. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004; 31: 331-52 (Pubitemid 38581227)
18. De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA,. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 13: 1587-93 (Pubitemid 28465299)
19. Roberts S, Goldacre MJ,. Time trends and demography of mortality after fractured neck of femur in an English population, 1968-98: database study. BMJ 2003; 327: 771-4 (Pubitemid 37211166)
20. Van Daele PL, Seibel MJ, Burger H, et al,. Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 1996; 312: 482-3 (Pubitemid 26061239)
21. Smith MR, Fallon MA, Goode MJ,. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003; 6: 127-31 (Pubitemid 36151727)
22. Smith MR,. Complimentary and alternative therapies for advanced prostate cancer. Hematol Oncol Clin North Am 2001; 15: 559-71 (Pubitemid 32762174)